Taysha Gene Therapies, Inc.
TSHA
$5.95
-$0.04-0.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 5.49M | -- | 1.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 5.49M | -- | 1.99M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 5.49M | -- | 1.99M |
| SG&A Expenses | 12.15M | 9.68M | 8.83M | 8.28M | 8.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -3.43M | -- | -- | -- | -- |
| Total Operating Expenses | 47.35M | 43.49M | 33.79M | 34.02M | 28.74M |
| Operating Income | -47.35M | -43.49M | -28.30M | -34.02M | -26.75M |
| Income Before Tax | -46.64M | -42.41M | -27.85M | -32.73M | -26.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.64M | -42.41M | -27.85M | -32.73M | -26.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.64M | -42.41M | -27.85M | -32.73M | -26.88M |
| EBIT | -47.35M | -43.49M | -28.30M | -34.02M | -26.75M |
| EBITDA | -47.06M | -43.19M | -28.00M | -33.74M | -26.48M |
| EPS Basic | -0.13 | -0.12 | -0.08 | -0.09 | -0.09 |
| Normalized Basic EPS | -0.08 | -0.07 | -0.04 | -0.06 | -0.05 |
| EPS Diluted | -0.13 | -0.12 | -0.08 | -0.09 | -0.09 |
| Normalized Diluted EPS | -0.08 | -0.07 | -0.04 | -0.06 | -0.05 |
| Average Basic Shares Outstanding | 369.04M | 366.63M | 357.32M | 353.31M | 297.99M |
| Average Diluted Shares Outstanding | 369.04M | 366.63M | 357.32M | 353.31M | 297.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |